A Slow- Compared with a Fast-Release Form of Oral Arginine Increases Its Utilization for Nitric Oxide Synthesis in Overweight Adults with Cardiometabolic Risk Factors in a Randomized Controlled Study
| Autor: | Robert Benamouzig, Etienne André, Pierre Bunouf, Jean-François Huneau, Frédérique Lantoine-Adam, Véronique Mathé, Hélène Fouillet, Klaus J. Petzke, François Mariotti, Dominique Hermier, Ambre Deveaux |
|---|---|
| Přispěvatelé: | Physiologie de la Nutrition et du Comportement Alimentaire (PNCA), AgroParisTech-Institut National de la Recherche Agronomique (INRA), Université Paris-Saclay, German Institute of Human Nutrition Potsdam-Rehbrücke (DIfE), Centre de Recherche Pierre Fabre, Centre de recherche Pierre Fabre, Institut National de la Recherche Agronomique (INRA)-AgroParisTech, Centre de Recherche Pierre Fabre (Centre de R&D Pierre Fabre), PIERRE FABRE |
| Rok vydání: | 2016 |
| Předmět: |
Adult
Male 0301 basic medicine medicine.medical_specialty Waist Adolescent Arginine [SDV]Life Sciences [q-bio] Biological Availability Medicine (miscellaneous) Blood lipids dietary arginine 030204 cardiovascular system & hematology Overweight metabolic syndrome Young Adult 03 medical and health sciences 0302 clinical medicine Metabolic Diseases Risk Factors nitric oxide Internal medicine medicine Humans oxyde nitrique 2. Zero hunger Cross-Over Studies syndrome métabolique Nutrition and Dietetics business.industry arginine metabolism metabolic x syndrome Middle Aged isotopic methods métabolisme de l'arginine medicine.disease Obesity 3. Good health Bioavailability 030104 developmental biology Endocrinology Cardiovascular Diseases Female medicine.symptom Metabolic syndrome business Body mass index |
| Zdroj: | Journal of Nutrition Journal of Nutrition, American Society for Nutrition, 2016, 146 (7), pp.1322-1329. ⟨10.3945/jn.116.231910⟩ |
| ISSN: | 0022-3166 |
| DOI: | 10.3945/jn.116.231910 |
| Popis: | Background: Oral L-arginine supplements can have a beneficial effect on nitric oxide (NO)-related functions when subjects have cardiovascular disease risk factors. Objective: The study was designed to determine the utilization for NO synthesis of oral L-arginine as a function of the cardiometabolic risk and the speed of absorption by comparing immediate-release arginine (IR-Arg), as in supplements, and sustained-release arginine (SR-Arg), which mimics the slow release of dietary arginine. Methods: In a randomized, single-blind, 2-period crossover, controlled trial (1 wk of treatment, >2 wk of washout), using[N-15-(15)-N(guanidino)]-arginine for the first morning dose, we compared the bioavailability (secondary outcome) and utilization for NO synthesis (primary outcome) of 1.5 g IR- and SR-Arg 3 times/d in 12 healthy overweight [body mass index (BMI; in kg/m(2)): 25-30] adults with the hypertriglyceridemic waist phenotype [HTW; plasma triglycerides (TGs): >150 mg/dL; waist circumference: >94 cm (men) or >80 cm (women)] and 15 healthy control adults (CON; BMI: 18.5-25; no elevated TGs and waist circumference). Results: Plasma oral arginine areas under the curve were lower after supplementation with SR-Arg than with IR-Arg (112 +/- 52.3 and 142 +/- 50.8 mu mol . h/L; P < 0.01). The utilization of oral arginine for NO synthesis was 58% higher in HTW subjects than in CON subjects and higher with SR-Arg than with IR-Arg (P < 0.05 both), particularly in HTW subjects (group-by-treatment interaction, P < 0.05). In HTW subjects administered the SR form, utilization for NO synthesis was 32% higher than with the IR form and 87% higher than in CON subjects who were administered the SR form. Conclusion: In overweight adults with the HTW phenotype, a slow- compared with a fast-release form of oral arginine markedly favors the utilization of arginine for NO synthesis. The utilization of low-dose, slow-release arginine for NO synthesis is higher in overweight adults with the HTW phenotype than in healthy controls, suggesting that the sensitivity of NO synthesis to the dietary arginine supply increases with cardiometabolic risk. The trial was registered at clinicaltrials.gov as NCT02352740. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|